Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle-Invasive Bladder Cancer.,The Journal of Urology

当前位置： X-MOL 学术 › J. Urol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle-Invasive Bladder Cancer.
The Journal of Urology ( IF 5.9 ) Pub Date : 2021-08-27 , DOI: 10.1097/ju.0000000000002190
David D'Andrea ₁ , Peter C Black ₂ , Homayoun Zargar _{2,

3} , Colin P Dinney ₄ , Francesco Soria ₅ , Michael S Cookson ₆ , Jeffrey S Montgomery ₇ , Wassim Kassouf ₈ , Marc A Dall'Era ₉ , Srikala S Sridhar ₁₀ , John S McGrath ₁₁ , Jonathan L Wright ₁₂ , Andrew C Thorpe ₁₃ , Jeff M Holzbeierlein ₁₄ , Diego M Carrión ₁₅ , Ettore Di Trapani ₁₆ , Trinity J Bivalacqua ₁₇ , Scott North _{18,

19} , Daniel A Barocas ₂₀ , Yair Lotan ₂₁ , Petros Grivas _{22,

23} , Andrew J Stephenson ₄ , Bas W van Rhijn ₂₄ , Siamak Daneshmand ₂₅ , Philippe E Spiess ₂₆ , Shahrokh F Shariat _{1,

21,

27,

28,

29} , _{7,

30,

31,

32,

33,

34,

35,

36,

37,

38,

39,

40}

Affiliation

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Department of Urology, Western Health, Melbourne, Australia.
Department of Urology, MD Anderson Cancer Center, Houston, Texas.
Department of Urology, Molinette Hospital, University of Turin, Turin, Italy.
Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma.
Department of Urology, University of Michigan Health System, Ann Arbor, Michigan.
Department of Surgery (Division of Urology), McGill University Health Center, Montreal, Canada.
Department of Urology, University of California at Davis, Davis Medical Center, Sacramento, California.
Princess Margaret Hospital, Toronto, Ontario, Canada.
Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, UK.
Department of Urology, University of Washington, Seattle, Washington.
Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK.
Department of Urology, University of Kansas Medical Center, Kansas City, Kansas.
Department of Urology, Louisiana Paz University Hospital, Madrid, Spain.
Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy.
Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland.
Cross Cancer Institute, Edmonton, Alberta, Canada.
Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.
Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, Washington.
Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Department of Urology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, California.
Department of Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Departments of Urology, Weill Cornell Medical College, New York, New York.
Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic.
Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
University of Auckland, Auckland, New Zealand.
University of Alberta, Edmonton, Alberta, Canada.
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain.
Department of Urology, University of Münster, Münster, Germany.
Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Stevenage, UK.
Department of Urology, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France.
Department of Urology, Medical University Innsbruck, Innsbruck, Austria.
Bristol Urological Institute, North Bristol NHS Trust, Bristol, UK.
Department of Urology, Stanford University School of Medicine, Stanford, California.
Department of Urology, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy.

To investigate the pathologic response rates and survival associated with 3 versus 4 cycles of cisplatin-based NAC in patients with cT2-4N0M0 MIBC.

中文翻译：